Amgen Acquires Dark Blue Therapeutics To Advance DBT 3757 For Acute Leukemia

Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leu...

January 07, 2026 | Wednesday | News
WuXi Biologics Achieves ISO 20400 Sustainable Procurement Certification, Strengthening Global Supply Chain Resilience

WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrate...

January 06, 2026 | Tuesday | News
Biohaven Reports Phase 2 Results for BHV-7000 in Major Depressive Disorder

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...

December 26, 2025 | Friday | News
Caliway Submits FDA IND for Phase 2 Study of CBL-514 in Combination With Eli Lilly’s Zepbound® for Weight Management

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical...

December 26, 2025 | Friday | News
Orchestrating Scale In Cell And Gene Therapy From Trial Complexity To Commercial Reality

As cell and gene therapies move rapidly from pioneering clinical trials into commercial healthcare systems the industry is facing a defining inflection poi...

December 25, 2025 | Thursday | Interaction
Neupulse Launches Drug-Free Wearable Offering New Hope for People Living With Tourette Syndrome

Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...

December 17, 2025 | Wednesday | News
The CEO Playbook For Biopharma In An Age Of Regulatory And Market Volatility

Biopharmaceutical leaders today are charting a course through unprecedented regulatory uncertainty and market turbulence. From shifting FDA and EMA approva...

December 16, 2025 | Tuesday | Analysis
Tjoapack Announces Major U.S. Expansion with New 170,000-sq-ft Pharmaceutical Packaging Facility

Tjoapack, a leading global contract packaging organization, has announced a significant strategic investment to expand its operational footprint in the U.S...

December 10, 2025 | Wednesday | News
Pfizer Phase 3 BASIS Study Shows HYMPAVZI Delivers 93% Bleed Reduction in Hemophilia With Inhibitors

-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...

December 08, 2025 | Monday | News
Sarepta Receives FDA Approval to Initiate Cohort 8 Evaluating Sirolimus With ELEVIDYS in Non-Ambulant Duchenne

Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to be...

November 26, 2025 | Wednesday | News
MDA Applauds FDA Approval of Itvisma, the First Gene Replacement Therapy for a Broad SMA Population

The Muscular Dystrophy Association (MDA)  called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), ...

November 26, 2025 | Wednesday | News
AGC Biologics Partners with AAVantgarde to Advance Dual-Vector AAV Gene Therapies for Inherited Blindness

Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blin...

November 24, 2025 | Monday | News
Purdue Pharma Reports Positive Phase 1 Results for Tinostamustine in Difficult-to-Treat Glioblastoma

Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. -...

November 20, 2025 | Thursday | Reports
Thermo Fisher Opens Flagship United States Center in Philadelphia to Accelerate Cell & Gene Therapy Development

  New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...

November 19, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close